<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869725</url>
  </required_header>
  <id_info>
    <org_study_id>201212736</org_study_id>
    <secondary_id>NCI-2013-00936</secondary_id>
    <secondary_id>P30CA086862</secondary_id>
    <secondary_id>R01CA167632</secondary_id>
    <nct_id>NCT01869725</nct_id>
  </id_info>
  <brief_title>Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT</brief_title>
  <official_title>Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sue O'Dorisio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies gallium Ga 68-edotreotide positron emission tomography&#xD;
      (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus&#xD;
      contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other&#xD;
      somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga&#xD;
      68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive&#xD;
      neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective&#xD;
      as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of&#xD;
      patients with neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To compare efficacy of [68Ga]-DOTA-tyr3-Octreotide (68Ga-DOTATOC) (gallium Ga&#xD;
      68-edotreotide) PET/CT with Octreoscan (indium In 111 pentetreotide) + high-resolution,&#xD;
      contrast-enhanced CT for diagnosis and staging in patients with somatostatin receptor&#xD;
      expressing tumors.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive gallium Ga 68-edotreotide intravenously (IV) and undergo PET/CT scan. Within&#xD;
      120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI&#xD;
      scan. Patients may also undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6&#xD;
      months if the lesions of the first scan cannot be confirmed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2013</start_date>
  <completion_date type="Actual">December 26, 2018</completion_date>
  <primary_completion_date type="Actual">December 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Conventional Imaging and Gallium Ga 68-edotreotide PET Using Concordance in Tumor Detection With Pathology</measure>
    <time_frame>Up to 6 months between the timing of the Octreoscan SPECT/CT plus high-resolution, contrast-enhanced CT and the time of the 68Ga-DOTATOC PET/CT (either imaging type may occur first)</time_frame>
    <description>Tumor lesions detected on 68Ga-DOTATOC PET/CT compared with tumor lesions detected on Octreoscan SPECT imaging plus high-resolution, contrast-enhanced CT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare Sensitivity of 68Ga-DOTATOC PET/CT With Octreoscan</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Compare sensitivity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare Specificity of 68Ga-DOTATOC PET/CT With Octreoscan</measure>
    <time_frame>6 months</time_frame>
    <description>Compare specificity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Adult Medulloblastoma</condition>
  <condition>Childhood Medulloblastoma</condition>
  <condition>Neuroblastoma</condition>
  <condition>Neuroendocrine Tumor</condition>
  <condition>Somatostatinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (gallium Ga 68-edotreotide PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gallium Ga 68-edotreotide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (gallium Ga 68-edotreotide PET/CT)</arm_group_label>
    <other_name>Ga-68 DOTA0-Tyr3-octreotide</other_name>
    <other_name>Ga-68 DOTATOC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography/computed tomography</intervention_name>
    <description>Undergo gallium Ga 68-edotreotide PET/CT scan</description>
    <arm_group_label>Diagnostic (gallium Ga 68-edotreotide PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 pentetreotide</intervention_name>
    <description>Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan</description>
    <arm_group_label>Diagnostic (gallium Ga 68-edotreotide PET/CT)</arm_group_label>
    <other_name>Indium-111 Octreotide DTPA</other_name>
    <other_name>Indium-111-DTPA-D-Phe-1-octreotide</other_name>
    <other_name>Indium-In 111 Pentetreotide</other_name>
    <other_name>Indium-In-111-Pentetreotide</other_name>
    <other_name>Octreoscan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Undergo indium In 111 pentetreotide contrast-enhanced CT scan</description>
    <arm_group_label>Diagnostic (gallium Ga 68-edotreotide PET/CT)</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>contrast-enhanced magnetic resonance imaging</intervention_name>
    <description>Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan</description>
    <arm_group_label>Diagnostic (gallium Ga 68-edotreotide PET/CT)</arm_group_label>
    <other_name>Contrast-enhanced MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Biopsy proven neuroendocrine tumor, neuroblastoma, medulloblastoma, or other&#xD;
             somatostatin receptor positive tumor&#xD;
&#xD;
          -  Off Sandostatin (octreotide acetate)-long acting release (LAR) &gt; 4 weeks and off&#xD;
             immediate release (subcutaneous) for 12 hrs prior to 68Ga-DOTATOC PET-CT&#xD;
&#xD;
          -  Karnofsky performance status or Lansky Play Scale status of &gt;= 50 (or Eastern&#xD;
             Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)&#xD;
&#xD;
          -  Subject is male; or is a female who is either pre-menarchal, surgically sterile (has&#xD;
             had a documented bilateral oophorectomy and/or documented hysterectomy),&#xD;
             postmenopausal (&gt; 1 years without menses), non-lactating, or of childbearing potential&#xD;
             for whom a serum pregnancy test (with the results known prior to investigational&#xD;
             product administration) is negative; a negative serum pregnancy test will be required&#xD;
             for all female subjects with child bearing potential; if a false pregnancy test is&#xD;
             suspected, e.g., perimenopausal condition, an obstetrician will be consulted to&#xD;
             determine if she is/is capable of becoming pregnant&#xD;
&#xD;
          -  No therapy other than Sandostatin since last Octreoscan + diagnostic CT&#xD;
&#xD;
          -  Fresh frozen (recommended) or paraffin fixed (required) specimen of primary or&#xD;
             metastases available for ribonucleic acid (RNA) and immunohistochemistry (IHC)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Surgical resection, chemotherapy, radiation therapy, or biologic therapy since last&#xD;
             Octreoscan + CT; continuation of the same dose of Sandostatin-LAR or subcutaneous&#xD;
             Sandostatin is allowed&#xD;
&#xD;
          -  Medical condition uncontrolled by treatment making completion of study unlikely&#xD;
&#xD;
          -  Weight more than 400 pounds (subjects who weigh more than 400 pounds will not be able&#xD;
             to fit inside the imaging machines)&#xD;
&#xD;
          -  Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,&#xD;
             etc.)&#xD;
&#xD;
          -  Inability to complete the needed investigational and standard-of-care imaging&#xD;
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)&#xD;
&#xD;
          -  Any additional medical condition, serious intercurrent illness, or other extenuating&#xD;
             circumstance that, in the opinion of the investigator, may significantly interfere&#xD;
             with study compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Sue O' Dorisio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 31, 2013</study_first_submitted>
  <study_first_submitted_qc>May 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <results_first_submitted>July 30, 2021</results_first_submitted>
  <results_first_submitted_qc>August 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2021</results_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Sue O'Dorisio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Neuroendocrine Tumor</keyword>
  <keyword>Ga-DOTATOC PET</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Somatostatinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
    <mesh_term>Indium-111-octreotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT01869725/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT01869725/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (Gallium Ga 68-edotreotide PET/CT)</title>
          <description>Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.&#xD;
gallium Ga 68-edotreotide: Given IV&#xD;
positron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan&#xD;
indium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan&#xD;
computed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan&#xD;
contrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ineligible after registration</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>68 patients enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (Gallium Ga 68-edotreotide PET/CT)</title>
          <description>Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.&#xD;
gallium Ga 68-edotreotide: Given IV&#xD;
positron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan&#xD;
indium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan&#xD;
computed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan&#xD;
contrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="4" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>eligible participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Conventional Imaging and Gallium Ga 68-edotreotide PET Using Concordance in Tumor Detection With Pathology</title>
        <description>Tumor lesions detected on 68Ga-DOTATOC PET/CT compared with tumor lesions detected on Octreoscan SPECT imaging plus high-resolution, contrast-enhanced CT.</description>
        <time_frame>Up to 6 months between the timing of the Octreoscan SPECT/CT plus high-resolution, contrast-enhanced CT and the time of the 68Ga-DOTATOC PET/CT (either imaging type may occur first)</time_frame>
        <population>Patients with neuroendocrine tumor or other somatostatin receptor positive tumor</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Gallium Ga 68-edotreotide PET/CT)</title>
            <description>Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.&#xD;
gallium Ga 68-edotreotide: Given IV&#xD;
positron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan&#xD;
indium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan&#xD;
computed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan&#xD;
contrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Conventional Imaging and Gallium Ga 68-edotreotide PET Using Concordance in Tumor Detection With Pathology</title>
          <description>Tumor lesions detected on 68Ga-DOTATOC PET/CT compared with tumor lesions detected on Octreoscan SPECT imaging plus high-resolution, contrast-enhanced CT.</description>
          <population>Patients with neuroendocrine tumor or other somatostatin receptor positive tumor</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity and Specificity for Ga-68-DOTATOC as Compared to Pathology</title>
              <category_list>
                <category>
                  <title>Total positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>False position</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>False negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Total negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitivity and Specificity for OctreoScan as Compared to Pathology</title>
              <category_list>
                <category>
                  <title>Total positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>False position</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>False negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Total negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compare Sensitivity of 68Ga-DOTATOC PET/CT With Octreoscan</title>
        <description>Compare sensitivity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors</description>
        <time_frame>Up to 6 months</time_frame>
        <population>Patients with neuroendocrine tumor or other somatostatin receptor positive tumor</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Gallium Ga 68-edotreotide PET/CT)</title>
            <description>Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.&#xD;
gallium Ga 68-edotreotide: Given IV&#xD;
positron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan&#xD;
indium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan&#xD;
computed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan&#xD;
contrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Sensitivity of 68Ga-DOTATOC PET/CT With Octreoscan</title>
          <description>Compare sensitivity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors</description>
          <population>Patients with neuroendocrine tumor or other somatostatin receptor positive tumor</population>
          <units>percentage of sensitivity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity of Ga-68-DOTATOC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitivity of OctreoScan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitivity of Conventional Imaging (CI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compare Specificity of 68Ga-DOTATOC PET/CT With Octreoscan</title>
        <description>Compare specificity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors</description>
        <time_frame>6 months</time_frame>
        <population>Patients with neuroendocrine tumor or other somatostatin receptor positive tumor</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Gallium Ga 68-edotreotide PET/CT)</title>
            <description>Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.&#xD;
gallium Ga 68-edotreotide: Given IV&#xD;
positron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan&#xD;
indium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan&#xD;
computed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan&#xD;
contrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Specificity of 68Ga-DOTATOC PET/CT With Octreoscan</title>
          <description>Compare specificity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors</description>
          <population>Patients with neuroendocrine tumor or other somatostatin receptor positive tumor</population>
          <units>percentage of specificity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Specificity of 68Ga-DOTATOC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity of Octreoscan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity of Conventional Imaging (CI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over 6 months at the following time points: 1) screening visit which occurred within 30 days of Ga-68 DOTATOC PET/CT 2) at scan 1 3) 1-7 days post scan 1 4) at scan 2 5) 1-7 days post scan 2</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (Gallium Ga 68-edotreotide PET/CT)</title>
          <description>Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.&#xD;
gallium Ga 68-edotreotide: Given IV&#xD;
positron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan&#xD;
indium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan&#xD;
computed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan&#xD;
contrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <description>cramping</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <description>chills</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <description>joint stiffness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <description>skin mottling</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although 67/68 were eligible and received the 68Ga-DOTATOC PET scan, four patients did not receive the 111In-Octreotide SPECT scan. Of the 63 subjects who received both scans, 30 subjects did not receive the 111In-Octreotide SPECT scan within either the six months prior to or six months after the 68Ga-DOTATOC PET scan. This left only 34 subjects who could be fully evaluated for comparison of number of lesions found on both scans.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>M. Sue O'Dorisio, MD, PhD</name_or_title>
      <organization>University of Iowa</organization>
      <phone>319-335-7234</phone>
      <email>sue-odorisio@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

